#Canada #Ontario #Osteoarthritis #Contura Orthopedics #Arthrosamid

Contura Orthopedics Expands to Canada

Contura Orthopedics has proudly announced the establishment of its Canadian branch, Contura Orthopedics (Canada) Ltd., marking a significant progress in the company’s global strategy. This move follows Health Canada's approval of Arthrosamid®, a cutting-edge hydrogel treatment created for individuals suffering from knee pain attributable to osteoarthritis (OA), a condition that affects millions.

Addressing Osteoarthritis: A Growing Concern

Osteoarthritis stands as the most prevalent form of arthritis worldwide, affecting approximately 4 million Canadians alone. This debilitating condition can severely impact mobility, quality of life, and overall health. As the population ages, the demand for effective, sustainable pain management solutions becomes increasingly urgent. Unfortunately, current treatment options primarily include painkillers or steroid injections, which often only offer temporary relief, leaving many patients contemplating invasive procedures like knee replacement surgery.

Contura recognizes the pressing need for innovative solutions and has committed to bridging the existing gaps in treatment. The launch of Arthrosamid® aims to provide a much-needed alternative that not only alleviates pain but also enhances joint function over time.

Arthrosamid®: A Revolutionary Hydrogel Solution

Arthrosamid® (2.5% iPAAG) is a unique, permanent injectable hydrogel designed for the long-term management of knee osteoarthritis pain. Unlike other injectable treatments, Arthrosamid® integrates into the knee's synovial tissue after a single administration, delivering lasting relief without the need for surgical intervention. Clinical studies highlight the product’s effectiveness, showing sustained pain relief and improved mobility even four years post-treatment.

Leadership and Commitment to Canadian Patients

To spearhead its Canadian operations, Contura Orthopedics has appointed Peter Tomashewski as the Canadian Commercial Leader. Tomashewski brings a wealth of experience from the medical device and pharmaceutical sectors, making him a valuable asset as the company strives to get Arthrosamid® into the hands of those in need.

Rakesh Tailor, the CEO of Contura Group, expressed enthusiasm about this expansion into Canada: “This is a significant achievement for Contura as we endeavor to make Arthrosamid® available globally. Osteoarthritis poses a formidable public health challenge, and innovative non-surgical treatments are vital for enhancing patient outcomes.”

Peter Tomashewski echoed this sentiment, stating, “I’m exhilarated to join Contura at such a pivotal time. Arthrosamid® represents a groundbreaking advancement for Canadians facing knee pain due to osteoarthritis. I am eager to collaborate with healthcare professionals to expand access to this novel pain relief solution.”

Commitment to Excellence in Patient Care

Contura Orthopedics remains dedicated to enhancing patient care through the development and delivery of innovative and clinically validated solutions within the orthopedic field. This commitment is not only a testament to the company’s core values but also a crucial step forward in addressing the needs of millions suffering from knee osteoarthritis.

For further information on Contura Orthopedics and to learn more about Arthrosamid®, visit www.arthrosamid.com.